BioSilicon-based brachytherapy shows early promise for pSivida
This article was originally published in Clinica
Executive Summary
Early results from the first human tests of pSivida's BioSilicon-based brachytherapy technology have shown that the product is safe and effective in terms of tumour regression, the company has revealed.